Press releases
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates
More ▼
Key statistics
On Friday, Heron Therapeutics Inc (AXD2:DEU) closed at 3.30, -8.63% below its 52-week high of 3.62, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.23 |
---|---|
High | 3.49 |
Low | 3.23 |
Bid | 3.28 |
Offer | 3.39 |
Previous close | 3.29 |
Average volume | 1.21k |
---|---|
Shares outstanding | 150.65m |
Free float | 149.61m |
P/E (TTM) | -- |
Market cap | 575.50m USD |
EPS (TTM) | -0.6156 USD |
Data delayed at least 15 minutes, as of Jun 07 2024.
More ▼